1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Kidney Disease - Pipeline Review, H1 2014

Kidney Disease - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 106 pages

Kidney Disease - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Kidney Disease - Pipeline Review, H1 2014’, provides an overview of the Kidney Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Kidney Disease - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Kidney Disease Overview 10
Therapeutics Development 11
Pipeline Products for Kidney Disease - Overview 11
Pipeline Products for Kidney Disease - Comparative Analysis 12
Kidney Disease - Therapeutics under Development by Companies 13
Kidney Disease - Therapeutics under Investigation by Universities/Institutes 16
Kidney Disease - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Kidney Disease - Products under Development by Companies 20
Kidney Disease - Products under Investigation by Universities/Institutes 21
Kidney Disease - Companies Involved in Therapeutics Development 22
F. Hoffmann-La Roche Ltd. 22
Sanofi 23
Nektar Therapeutics 24
Chugai Pharmaceutical Co., Ltd. 25
LEO Pharma A/S 26
Teva Pharmaceutical Industries Limited 27
Zydus Cadila Healthcare Limited 28
Gentium S.p.A. 29
Celldex Therapeutics, Inc. 30
Osteologix Holdings Plc. 31
Ahn-Gook Pharmaceutical Co., Ltd. 32
DiaMedica Inc. 33
Upsher-Smith Laboratories, Inc. 34
TetraLogic Pharmaceuticals 35
ChemoCentryx, Inc. 36
Anexon, Inc. 37
Otsuka Holdings Co., Ltd. 38
BIOPROJET SCR 39
Advicenne Pharma 40
ZS Pharma, Inc. 41
G1 Therapeutics, Inc. 42
AbbVie Inc. 43
Kidney Disease - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Target 45
Assessment by Mechanism of Action 48
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
ADV-7809 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
benazepril hydrochloride - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
ADV-7103 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
tolvaptan - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
methylprednisolone - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
ZS-9 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
AGNPN-803 - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
hydrocodone bitartrate ER - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
LEO-27847 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
DM-199 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
tiprolisant - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
ABT-614 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
ANX-042 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
CCX-872 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
RG-7641 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
CDX-1189 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
CU-NP - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Necrostatin Program - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Oligotide - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
NKTR-228 - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
CCR2 Antagonist - Drug Profile 78
Product Description 78
Mechanism of Action 78
RandD Progress 78
CH-5451098 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
SkQR-1 - Drug Profile 80
Product Description 80
Mechanism of Action 80
RandD Progress 80
TNT-009 - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
SLR-080811 Derivative - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
AVE-0991 - Drug Profile 83
Product Description 83
Mechanism of Action 83
RandD Progress 83
NBS-101 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
Prod-1 - Drug Profile 85
Product Description 85
Mechanism of Action 85
RandD Progress 85
messenger RNA Therapeutics Program - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
AHRO-200 - Drug Profile 87
Product Description 87
Mechanism of Action 87
RandD Progress 87
CDK-4/6 Inhibitors As Renal Protectants - Drug Profile 88
Product Description 88
Mechanism of Action 88
RandD Progress 88
A77-Based Monobody - Drug Profile 89
Product Description 89
Mechanism of Action 89
RandD Progress 89
Kidney Disease - Recent Pipeline Updates 90
Kidney Disease - Dormant Projects 98
Kidney Disease - Product Development Milestones 99
Featured News and Press Releases 99
Nov 07, 2013: La Jolla Pharmaceutical Company Presents Data at the Annual American Society of Nephrology Conference 99
May 02, 2013: Arena Pharma Withdraws European Marketing Authorization Application For Belviq 99
Mar 28, 2013: Cytori Therapeutics Receives US Patent Covering Method Of Treating Renal Diseases Using Adipose-derived Regenerative Cells 99
Jan 08, 2013: Medicure Announces Filing Of sNDA For Aggrastat Label Change 100
Nov 06, 2012: Lexicon Pharma Presents Phase IIb Results Of LX4211 At American Heart Association Annual Conference 101
Oct 17, 2012: Raptor Pharma Announces Presentation Of Procysbi Extension Study Data At American Society Of Nephrology Annual Meeting 102
Aug 03, 2012: New Published Data Demonstrate Endocyte's Targeted Small Molecule Drug Conjugate Approach Shows Promising Results In Polycystic Kidney Disease Model 102
Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease 103
May 11, 2011: Rockwell Medical Receives US Patent For SFP Packaging And Method Of Use 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables

Number of Products under Development for Kidney Disease, H1 2014 11
Number of Products under Development for Kidney Disease - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Investigation by Universities/Institutes, H1 2014 21
Kidney Disease - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 22
Kidney Disease - Pipeline by Sanofi, H1 2014 23
Kidney Disease - Pipeline by Nektar Therapeutics, H1 2014 24
Kidney Disease - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 25
Kidney Disease - Pipeline by LEO Pharma A/S, H1 2014 26
Kidney Disease - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 27
Kidney Disease - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 28
Kidney Disease - Pipeline by Gentium S.p.A., H1 2014 29
Kidney Disease - Pipeline by Celldex Therapeutics, Inc., H1 2014 30
Kidney Disease - Pipeline by Osteologix Holdings Plc., H1 2014 31
Kidney Disease - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 32
Kidney Disease - Pipeline by DiaMedica Inc., H1 2014 33
Kidney Disease - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 34
Kidney Disease - Pipeline by TetraLogic Pharmaceuticals, H1 2014 35
Kidney Disease - Pipeline by ChemoCentryx, Inc., H1 2014 36
Kidney Disease - Pipeline by Anexon, Inc., H1 2014 37
Kidney Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2014 38
Kidney Disease - Pipeline by BIOPROJET SCR, H1 2014 39
Kidney Disease - Pipeline by Advicenne Pharma, H1 2014 40
Kidney Disease - Pipeline by ZS Pharma, Inc., H1 2014 41
Kidney Disease - Pipeline by G1 Therapeutics, Inc., H1 2014 42
Kidney Disease - Pipeline by AbbVie Inc., H1 2014 43
Assessment by Monotherapy Products, H1 2014 44
Number of Products by Stage and Target, H1 2014 47
Number of Products by Stage and Mechanism of Action, H1 2014 50
Number of Products by Stage and Route of Administration, H1 2014 52
Number of Products by Stage and Molecule Type, H1 2014 54
Kidney Disease Therapeutics - Recent Pipeline Updates, H1 2014 90
Kidney Disease - Dormant Projects, H1 2014 98

List of Figures
Number of Products under Development for Kidney Disease, H1 2014 11
Number of Products under Development for Kidney Disease - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 44
Number of Products by Top 10 Target, H1 2014 45
Number of Products by Stage and Top 10 Target, H1 2014 46
Number of Products by Top 10 Mechanism of Action, H1 2014 48
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 49
Number of Products by Top 10 Route of Administration, H1 2014 51
Number of Products by Stage and Top 10 Route of Administration, H1 2014 52
Number of Products by Top 10 Molecule Type, H1 2014 53
Number of Products by Stage and Top 10 Molecule Type, H1 2014 54

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Polycystic kidney disease (PKD)- Market Insights, Epidemiology and Market Forecast-2023

Polycystic kidney disease (PKD)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Polycystic kidney disease (PKD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Polycystic kidney disease (PKD) - Epidemiology Forecast To 2023

Polycystic kidney disease (PKD) - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Polycystic kidney disease (PKD) - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Polycystic kidney disease (PKD) in seven major markets (US, France, ...

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • September 2016
  • by Global Data

Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Anemia in Chronic Kidney Disease (Renal Anemia) Global Clinical Trials ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.